On February 17, 2009, President Obama signed into law the American Recovery and Reinvestment Act of 2009, commonly referred to as the media as the Stimulus Bill.

Among its many provisions, the Act provided $1.1 billion for comparative effectiveness research (CER). This expansion of funding for CER, the largest ever federal investment in CER, carries significant potential opportunities and risks for industry, patients, and doctors.

Overview of the CER Provisions of the Act